Axcelis Technologies Inc (ACLS) 2020 Q3 法說會逐字稿

Good day, ladies and gentlemen, and welcome to the Axcelis Technologies call to discuss the company's results for the Third Quarter 2020. My name is Katherine and I'll be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to your host for today's call. Mary Puma, President and CEO of Axcelis Technologies. Please go ahead, ma'am.

Thank you, Katherine. With me today is Kevin Brewer, Executive Vice President and CFO; and Doug Lawson, Executive Vice President of Corporate Marketing and Strategy. We are all participating in this call remotely. So I would like to apologize in advance for any technical difficulties. If you have not seen a copy of our press release issued last night, it is available on our website. Playback service will also be available on our website as described in our press release. Please note that comments made today about our expectations for future revenues, profits and other results are forward-looking statements under the SEC Safe Harbor Provision.

These forward-looking statements are based on management's current expectations and are subject to the risks inherent in our business. These risks are described in detail in our Form 10-K annual report and other SEC filings, which we urge you to review. Our actual results may differ materially from our current expectations. We do not assume any obligation to update these forward-looking statements.

Good morning, and thank you for joining us. 2020 has certainly proven to be an unusual year. Despite this, Axcelis has maintained a focus on driving Purion growth in key markets while addressing the many twists and turns the year has brought.

Let's start with our top priority, which is the health of our employees operating in the COVID-19 environment. Through the implementation of recommended safety protocols, we continue to run our Beverly Facility at full manufacturing and lab capacity with all other employees working from home.

Our field teams around the world are operating according to their local guidelines and are working closely with our customers to ensure that we are able to satisfy their requirements in a safe manner.

I would like to personally thank our extraordinary employees around the world, who are working diligently to meet our customer commitments. I also want to thank our suppliers and customers for their support, as we strive to meet the continuing high level of customer interest in our Purion products. Our third quarter financial performance met or exceeded guidance and consensus. Revenue for the third quarter was $110.4 million with earnings per share of $0.32, gross margins of 43.6% and a cash balance of $212.7 million at quarter end.

Our aftermarket business or what we refer to a CS&I, once again contributed significantly to our revenue and gross margin. The mature process technology markets continue to be an area of strength for Axcelis, which has been critical during this longer than expected memory slow down.

This is especially highlighted in the third quarter where 100% of our system shipments went to mature foundry logic customers. China has also been a strong market for Axcelis this year. With the strength continuing through the third quarter, the geographic mix of our system shipments in the third quarter was China 66%, Korea 20%, Japan 8%, and Europe 6%.

This mix highlights the strength of the mature foundry logic market in both China and Korea. We expect there will be some memory shipments in Q4. Although the quarter will be heavily weighted towards mature foundry logic.

China will also continue to account for a significant percentage of our fourth quarter shipments.

During the third quarter, the US government imposed new restrictions on sales of certain semiconductor equipment and materials to the Chinese foundry customer SMIC. SMIC is an important Axcelis customer, especially in the mature process technology market. We have thoroughly assessed the new restrictions. Tools and parts that are affected will require a license to ship in the future. After careful examination of our systems and the mature applications they are used for. We currently expect that we will receive licenses as needed for SMIC shipments.

Now turning to guidance. For the fourth quarter, we expect revenue of approximately $110 million, gross margins of approximately 41%, operating profit of approximately $10 million and earnings per share of approximately $0.21. Using Q4 guidance, Axcelis revenues will be up 35% year-over-year. This is strong performance given the memory is expected to account for less than 35% of total revenues in 2020. When memory spending does strengthen, Axcelis will be well positioned to achieve our 550 and $650 million target models over the next several years.

Continued growth of Purion products is the key to achieving our long-term business models. During the third quarter, we shipped 3 new Purion high current product evaluations. We shipped the first Purion 200 to a leading power device company. The power device market is a critical market for Axcelis and the Purion H200 is expected to play a key role in increasing our customer base and market share in this segment.

The other 2 evaluations are for Purion H systems. The first ship to a leading advanced logic customer. The advanced logic market segment is a key focus for our $650 million model. The second Purion H ship to enhance customer that currently uses the Purion XE. Expanding our Purion footprint at existing customers is a critical element of our long-term strategies for both the 550 and $650 million models.

At the end of Q3, we had 6 evaluation systems in the field. These evaluations represent the acceptance of our new products, penetration into new market segments and expansion of our product footprint within an existing customer. This includes the Purion VXE and Purion XEmax both focused on image sensors. A Purion H200 for power devices. A Purion Dragon for DRAM applications. A Purion H for advanced logic and second Purion H for NAND application. We expect to ship additional evaluation units over the next year as we continue to work closely with customers on further Purion adoption. Before Kevin reviews the financials, I would like to summarize 4 key takeaways. First, the mature process technology market is very strong and growing and Axcelis is the ion implant market leader in this segment.

Second, China will continue to be an important market for Axcelis and we currently expect that we will receive licenses as needed for SMIC shipments. Third, memory is expected to recover in 2021 and will be additive to our strong mature process technology and Chinese business and fourth, the Purion product family is extremely well-positioned to support this future growth.

Now I'd like to turn it over to Kevin to discuss our financials and some operational details, Kevin.

Thank you, Mary, and good morning. Axcelis delivered solid 3rd quarter performance. Thanks for the continuing outstanding work of our employees and supply chain partners. Strong gross margin performance with in-line revenue drove earnings per share well above company guidance and consensus estimates. During this ongoing pandemic, the health and well-being of our employees remains a top priority. We're doing our best to create a safe work environment for everyone at Axcelis.

For employees required to work in our factory, we're enforcing daily screening, physical distancing, and required use of facemask. Everyone who can work from home is working from home and they will continue to do so for now. Field-based teams are continuing to support our customers while following customer and country-specific protocol. Tool installations are being successfully completed by Axcelis employees, third-party support and created virtual solutions. We remain focused on our 550 and $650 million revenue models and are continuing to invest in products and sales channels required to achieve these target models. Additionally, we have been investing in manufacturing capability with new technologies and capital expenses and that improving productivity and capacity.

I will now turn to the third quarter results. Q3 revenue finished at $110.4 million compared to $123 million in Q2. Q3 system sales were $70.2 million compared to $76.8 million in Q2. Q3 CS&I revenue finished at $40.2 million compared to $46.2 million in Q2. Shipments of spare parts and consumables remained strong in the quarter, driven by fab utilization and customers likely maintaining a higher level of spare and inventory.

Q3 sales of our top 10 customers accounted for 76% of total sales, compared to 83.6% in Q2. Three customers were at 10% or above. Q3 system bookings were $26.4 million compared to $56.2 million in Q2 with a Q3 book-to-bill ratio of 0.37 versus 0.73 in Q2. Backlog in Q3 including deferred revenue finished at $45.1 million compared to $102.6 million in Q2.

Bookings and backlog can fluctuate quite a bit for the quarter to the specific order and practices with some customers booking and billing within the same quarter. Q4 bookings to date already exceeded the entire third quarter. Q3 combined SG&A and R&D spending was $34.3 million or 31% of revenue compared to $35.5 million or 28.9% in Q2. SG&A in the quarter was $19.4 million, with R&D of $14.9 million. We expect Q4 operating expenses to be approximately $36 million to support numerous evaluation systems and some additional costs associated with the pandemic. Q3 gross margins 43.6% compared to 42.2% in Q2. Q3 gross margin was driven by strong CS&I contribution product mix and ongoing cost out efforts. Q4 gross margin is expected to be approximately 41%.

The full year gross margin also around 41%. Gross margins can fluctuate quarter-to-quarter based on the level of CS&I contribution, customer and product mix in the closure of the IC evaluation units. For ongoing cost out efforts and planned higher sales at our Purion product extensions, we expect gross margin to improve over time. It's highlighted in our 550 and $650 million target model. Operating profit in Q3 finished $13.9 million compared to $16.4 million in Q2. Q3 net income was $10.8 million or $0.32 per share and well above consensus compared to $13.3 million or $0.39 per share in Q2. We are forecasting pandemic related expense of approximately $1.8 million in Q4, but across the P&L. Inventory ended at $159.7 million compared to $149.2 million in Q2. Due to the timing of shipments and additional inventory to support evaluation tools, Q3 inventory turns excluding eval tools finished at 1.8 compared to 2.1 Q2. Q3 accounts payable were $24.3 million compared to $30.3 million in Q2. Q3 receivables of $45.2 million compared to $64.9 million in Q2. Q3 cash finished at $217.7 million compared to $197 million in Q2.

Cash from operations in the quarter was $19.1 million. Our stock repurchase program remains unfold as we continued to maintain a conservative cash strategy. We will be revisiting this for the Axcelis Board in Q4 and expect to develop plans to return capital to our investors moving forward. We're finishing 2020 with strong momentum and are excited about the prospects of the 2021 recovery in the memory and automotive market. They continued to make the necessary investments in our products and infrastructure needed for our $550 million to $650 million target models. Customers continued to have high expectations for our Purion products which we intend to achieve. Thank you, and I'll now turn the call back to Mary for closing comments.

Thank you, Kevin. We're pleased with our third quarter financial performance as well as our expected performance in 2020 overall. We're excited by recent and upcoming evaluation shipments of both new Purion product extensions and enhanced Purion based products that will keep Axcelis on track to achieve our target business models. Axcelis as a competitive Purion product line, a broad and diverse customer base, a strong balance sheet and a dedicated team of employees.

These are the strengths that will continue to drive our growth. Ultimately to the market leadership position in ion implantation. With that, I'd like to open it up for questions. Katherine?

(Operator Instructions) Our first question comes from Patrick Ho with Stifel.

Congrats on the nice quarter. Mary, maybe first off, in terms of the mature technology note, can you give a little more color of the types of devices that you saw strengthened during the third quarter and whether you see any changes in the fourth quarter in terms of the growth market mix in that segment.

So as we said the mature process technology market is very strong and it's growing and we see a lot of strengths in particular in the image sensor and just general mature foundry business. We see automotive recovering and that's going to be a positive for the power device market. We said that -- memory really hasn't recovered yet, so in Q3, we had no system shipments to the memory segment, but we do expect memory to come back a bit in Q4, so that will change the segment mix a bit, but in general the mature process technology segment is going to be our strongest segment in the fourth quarter and China actually for us is quite strong.

As you know, we had 66% of shipments in Q3. We'll continue to be strong in Q4 and I would say the majority of the business that we get from China is in the mature process technology segment. So we'll continue to see business come from that segment as well -- or from that region as well.

Hey, Patrick, it's Kevin. Just to add a little bit to that. So the mature foundry is running at very high utilization rates. And so in addition to the strength in image sensors, as Mary mentioned the power device market is starting to come back as automotive recovers. But a lot of the strength is in mature products related to just all the glue logic, although little parts that go into making gaming systems and in TVs and monitors and all that stuff that has benefited actually from the work from home environment.

So that's a little bit of a boost to the mature markets.

Great. That's helpful. Maybe, Kevin, as my follow-up question in terms of gross margins, you mentioned how CS&I [mix] as well as the cost out efforts. As we look at Q4, given the value evaluation units, you talked about, is that kind of the biggest impact on a quarter-to-quarter basis in terms of the variables that affect the December quarter gross margins.

Yes, so as you point out, Patrick, CS&I we've always kind of said that's accretive, so whenever we have a big mix of CS&I that certainly helps within the products themselves. We have that page and the investor presentation does show the relative Purion products with the high energy being that the highest gross margins at this point and the high current, medium current, kind of lag that, so if there is a product mix shift and there with more high energy versus high-current or more CS&I versus CNL systems, those all will move it. Evaluation tools as you point out, I mean those are typically margin drag so -- and given quarters when evals had, it does move our margins and even though this year we are it's going to be full year average of 41% is what I said. As you remember, we got off with a tough start in Q1.

We are in 38% range because we had several evals convert over, so going forward as the evals come in, they certainly can impact the quarter but depending what the rest of the mix is though and sometimes you can help alleviate some of that. If you have a perfect storm and you got a lot of high current with lower margins and a lot evals and I guess that's the perfect storm.

But I think the important point is that we are continuing to drive cost out. We've got our target models out there for 550 and $650 million and we have detailed road maps in place that we've been executing too as we move forward towards those models.

Our next question comes from Craig Ellis with B. Riley.

Congratulations on the good financial and strategic execution in the quarter. So Mary, I wanted to start off just by following up on some of your CS&I commentary, so the third quarter was the second consecutive quarter where we saw revenues above $40 million. Do you believe that the segment is resetting structurally higher into the low 40s? Or are we just seeing something that's more temporal in the near term with sales as we would think about Calendar 21 potential likely to go back to that mid-30s range?

Well, we're not going to give a forecast for 2021 at this point in time, but we have been saying in the past that CS&I or our service businesses runs around 30% of our revenues. Recently it's been running around 40% of our revenues and based on what we know today, that's a pretty good percentage. Basically, it goes back to what Doug just said. Right now, there is a high level of fab utilization at the foundries, particularly in China and we're also seeing customers in China maintain high minimum stock levels, given what's going on with the pandemic and some of the geopolitical risks, that we've all been talking about recently. So right now, I think the 40% range is a good place to be but again, we'll just have to wait and see what 2021 brings and again we're not going to give a forecast for that at this point.

Okay, that's helpful and certainly on the mature foundry side, we've seen absolutely abundant signs that foundry utilizations are very high and IBM is moving up. Going back to that China points, very helpful color on where you stand with license submissions or SMIC but can you just help us understand what the next steps are? When do you expect to receive licenses and Kevin, how do we think about the way you manage the inventory and other issues? So that once received, you can actually ship product on a time line that you would like.

So you know we talked, so the restrictions just came out recently, it was just the end of September and as a business, we've worked very, very hard to understand exactly what that means for us. We've worked very carefully with legal counsel, our outside trade attorneys, with semi, our industry group to just kind of keep abreast of the situation and help us work our way through it. So as I said, we've thoroughly assessed the new restrictions.

We have identified that there are Axcelis tools and parts, that will require license to ship in the future. You know we're going through all the steps that are required to meet the US government guidelines. And so at this point in time as I said, we have confidence that we're going to be granted the required licenses. So it's all in process at this point, Craig, there's really nothing more specific to give other than to say that.

And from an inventory point. Yes, go ahead.

From inventory point, Craig, we're going to -- we're driving ahead because Mary said we're confident at this point that these licenses will be granted. And again, we did a pretty thorough review on the technology, our tools are being used on to which gives us a little bit more comforts to in terms of our assumptions. So we're moving forward inventory whether it be for system sales or would be for CS&I and within our guidance, we've got everything factored and right now we think we're going to end up in Q4, with any potential impact of [placement].

Got it and then housekeeping. Kevin, can you identify, how many evaluation tools you have been incorporated into the fourth quarter guidance for OpEx.

Yes.

Go ahead.

Yes. So we currently have 60 evaluation tools in the field. I think it's probably double what we had at any point in time. If not double, pretty close to double. I mean, typically, we have 1, 2, maybe 3 tools out there, there is 6 right now. And there are additional eval tools plan to go out. So there's a lot of activity right now going on with the newer product extensions, a lot of interest in the product. So as we talked about, this is one of the things going forward that we can help with the margins too. More customers moving over to some of the product extensions or what the drag and types tools. So there is a substantial amount out there right now and it's likely to grow.

Pipeline problems, good for you.

Craig, just to add some color. So it kind of do the math on it there. Two evaluations going on in memory, ones Purion Dragon for DRAM, ones Purion H for NAND. We've got 3 in the mature process technology area. One is Purion H 200 for power devices. And then there are too high energy tools for image sensors and then there's one Purion H for advanced logic. So that's kind of the mix by segment, and then 4 of them are high current and 2 of them are high energy. So it's actually really a nice mix across all the segments that we play in and for the tools that we're really trying to see the market in. I mean having 4 high-current evaluations out there is very important, because as we've talked about high current, it is the largest segment in implant and that's an area where we think we can drive some significant growth. So it is very good and as Kevin said, we expect to put more out in the field to help us drive towards our 550 and 650 models.

Indeed and if I could lastly on housekeeping. Kevin, I would expect if you on the fourth quarter for OpEx. We would see some FICA and fringe costs in the first quarter. Anything else that we should be aware of as we look beyond 4Q.

No. And I think --I think I've said it before, that this $36 million range is in the range we're going to stay in for a while, especially as we have this number of eval is going out and then we've got the models out there on 550 and 650. It's that point as a percent of revenue, it's 25% at 550 model, 24% at 650 model. So -- but for now, we've got that -- we've been running a little bit of pandemic expenses, so they said that's cut across the P&L but it is heading everywhere, so I think that's $36 million range. We're here for a while at this point.

Our next question comes from Christian Schwab with Craig-Hallum.

Congratulations on the good execution in the quarter. I was between conference call, so I apologize if that has been addressed already. But after a prolonged memory slowdown that we kind of highlighted at the beginning of the call. Mary, how do you see the memory market recovery as we go through 2021.

Okay. So like others in the industry, we did see an increase in memory in the first half of 2020 and at the beginning of the year, we actually said that memory could account for about 35% of our systems revenues in 2020 and it's likely to come in slightly shy of that. We had, had no memory shipments in the third quarter. We do expect some in the fourth quarter, but we still expect memory spending to come back in 2021 and that's kind of where we're right now, we're continuing to watch it and talk to our customers and assess the situation.

And when you're talking to your customers, are you looking for potential recovery and more DRAM over NAND or a 50-50 mix or how does it look to you today as we come to the end of 2020.

Christian, it's Doug. The mix you remember for us, it's all about wafer starts. We don't participate significantly in NAND layer addition, so for NAND it's about wafer start additions and DRAM, we get a little bit with the shrink of more again on wafer starts. So into this quarter clearly, we've zero shipments, it is likely the bottom starts to pick up next quarter and then move through the year. It looks for us, it's kind of split right now between both DRAM and NAND and so a little bit is going to depend on how the customers decide to ramp and of course, which customers are ramping first. So I think both products, DRAM's pricing has been pretty flat and we're starting to see a lot of activity there. NAND, they've been adding layers over the last several months, several quarters actually. And so there's probably -- I need to add some wafer starts soon there. So I think we'll see both.

Our next question comes from Tom Diffely with D.A. Davidson.

Nice results in light of having no memory in the quarter, that's pretty good. So Mary, just following up on the China situation. Have you been given any kind of indication how long it takes to get a license? And having any other equipment companies receive licenses yet.

The answer is, we're just waiting and watching and talking to our peers through SEMI. At this point in time. I think everybody is just trying to learn what this all means. So the answer is at this point, we really don't know what the time line is, but as I said before, we have confidence we will be granted the required licenses.

Okay. Is this impacting your initial view of the fourth quarter though with some business had delayed to tell you work through the process.

Again, it's -- things move in and out of quarters. I can't say that it had a significant impact on the fourth quarter, but again we had a lot of work to do, it not just from a system standpoint, but think about all the parts that we sell. So the team has done a really nice job just digging through everything and pulling the pieces together. So at this point in time, Q4 is what it is and we will continue to move on and we've applied for what we need to apply for, and we'll see how the process plays out.

Okay. And then when you look at the evaluation tools in the field right now based on the feedback you're getting, which of the programs or end markets do you think will be the first to go to volume manufacturing for the new tools?

I actually think that -- I think memory will especially the high energy tools will come to fruition, which is mostly an image sensor, just because it's a very strong market and our customers have a lot of data on how our tools will perform there. Also, I'm sorry I said memory mature process technology and image sensors. I think the memory market will also when it ramps up, when we see memory recover. I think we will see some volume buys clearly from the high current tools that we're putting in both the Purion H and the Dragon. I think as you know putting a tool into advanced logic is a very long tedious process. It's at least one year of evaluation and then our customer in qualification. And then our customer has to work with their customer or customers to get approval to actually put it into production. So that's the one that will take, I think a little bit longer to see any volume buys on. And I think I actually mentioned in the script that's more directly tied to our $650 million model than the $550 million, which would indicate. It could be several years out before we start to see some volume tied to that.

Okay, great. And then finally, any update on how the evaluation in Japan is going with the older tool?

Well, it's not an older tool. We do have legacy tools in Japan and we've had those there for several years. So the evaluation is actually for a brand new Purion XE that went to a power device customer. It's been installed and is under qualification right now and it's actually going quite well. Is that what you were referring to?

That is, yes, sorry.

(Operator Instructions) Our next question comes from David Duley with Steelhead Securities.

I guess my first question is on the size of the market. I know that's not a big focus for you guys. But if you could just review what the overall size of the implant market is and specifically really what the high current portion of the market is now as a percentage of the overall market? And maybe just help us with, I think that's a really important area for you to pick up market share in. Do you have market share goals in this segment of the market or how should we think about your progress in penetrating this largest piece of the implant market?

So David, so the implant market, we've typically said is about $1 billion in size, kind of plus or minus 10% depending on where we're in the cycle. Our view at this point is that it's probably growing to be on the top end of that and we will probably be more like $1.1 billion. Again, we'll oscillate a little bit depending on the cycle. The growth is being caused by a couple of factors. One on the high energy side there's growth as a result of the image sensor market especially as well as to some degree the power device.

Those 2 segments are especially image sensor, very implant intensive and very high energy implant intensive. And their purchasing tools like the VXE and the XEmax, which are much higher ASPs. So that's driving the TAM up from that perspective. And then the high current side is also growing proportionately and that's growing as a result of more material modification requirements. And so as far as the exact share goes, we don't really track specifically on share because it's hard to get that data from everybody, but the estimate is that high-energy is 25% to 30% of those in the TAM, high current is 50% to 55% and medium current makes up the rest.

In high energy space, we do have very high market share and especially high market share in new key areas with products like the VXE. We think we're very well positioned for growth in high current with the Dragon product targeting some very specific productivity applications in low energy ranges and load high dose and then with the Purion H the newest version of the Purion H now looking at advanced logic as well as some new memory applications. Again, all of these are targeted at the more difficult challenging implants for our customers.

And as far as the CMOS and sensor market goes, do you have an idea about how big a section of the overall market that is? And obviously, it's growing and there's 3 or 4 key customers around the world, maybe comment on penetrating the Japanese customer or your progress, potentially getting into that customer?

Yes. So we don't comment on the exact size of the image sensor market because it's very difficult. A lot of image sensors are built in standard mature foundries, on standard mature logic process flows with some additional steps to do the image sensor piece. So it's difficult to really estimate that and we don't break out the specifics relative to the high energy piece, which is more specific to the image sensor market, so can't really give you exact implant market size for that.

The image sensor market as a whole is growing quite substantially. And then as far as the customer you're referring to, with all of the image sensors customers, we're really targeting utilizing the VXE and then the XEmax. The XEmax brings much higher energy levels, which are critical for the most advanced image sensors and maybe more importantly, the boost technology reduces the metals contamination issues quite substantially, which is an enabling capability for the advanced image sensors, so those will be the 2 things that leading the German sensor companies as a whole will be looking at.

Our next question comes from Mark Miller with The Benchmark Company.

I just wanted to clarify a couple of things, and the tool that you ship, the power device was at a high-energy tool, Purion H.

No. The power device evaluation, the tool was -- it was a Purion H 200, so it's a high current tool.

Okay. Purion H 200 and then, okay. I was talking to one that ship, there was a image sensor also shipment, what type of tool was that.

The 2 image sensor shipments were high-energy tool, there was an XEmax, and then a Purion XEmax and a Purion VXE.

Okay. Have you seen anything in terms of your competitor making any technological upgrades to their tools?

Our competitor is always making improvements. It's one of the things the customers like about having a strongly competitive market with Axcelis and our competitor is that we're continuously both improving our products, capabilities of our products, productivity levels and overall costing ownership for them, so the key for us is we believe that Purion Dragon is tremendously forward in terms of high current technology and the Purion XE, VXE, XEmax continue to also be market leaders in technology, but also in terms of their use in key growing markets like image sensor and power device.

Our next question comes from Quinn Bolton with Needham.

Yes, most of my questions have been asked, but just I guess Kevin wanted to come back to the gross margin revenue tied roughly flat sequentially yet margins down 250 basis points. Doesn't sound like the change in margin is really any kind of absorption issue, so is it really just product mix within systems, I mean, CS&I revenue, I think it sounds like it's roughly flat at about 40% of sales, so it feels like it's got to be either mix within the systems shipments or your expectations to recognize revenue on perhaps in lower margin eval tools. And so just trying to make sure I have got all the moving parts right.

Yes, Quinn. It's in Q4, it's the mix of the system mix, so there is a mix of basically the high current and high energy that's impacting the Q4 number.

Got it. Okay, thank you. And then on the Purion H eval unit going into NAND. I know you guys have very high share and high-energy applications for both NAND and DRAM. I just wanted to make sure that this Purion H is sort of TAM expansive for you as that customer rather than a Purion H coming into replace where high energy tool may have previously been used.

It is. It's actually a new customer for us and it's as a new customer, and it's a new fab. So it is -- it is expansion for us.

Thank you. This concludes the Q&A portion of the call. I will now turn the call back over to Mary Puma who will make a few closing remarks.

Thank you, Katherine. I'd like to thank you all for joining us today. We hope to talk with you virtually at several upcoming investor events. We will be participating in the Benchmark Conference next week. And in December, the CEO Summit and DA Davidson Semicap, Laser and Optical Conference. We also expect to conduct several virtual MDRs during the quarter as well. We thank you for your continued support and please stay healthy.

This concludes the presentation. Thank you for your participation in today's conference. You may now disconnect. Everyone have a great day.